We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+25.43%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$16.7B
AUM Growth
+$1.38B
Cap. Flow
-$374M
Cap. Flow %
-2.25%
Top 10 Hldgs %
86.98%
Holding
128
New
13
Increased
17
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$37.7M
2
PRME icon
Prime Medicine
PRME
+$18.6M
3
DNLI icon
Denali Therapeutics
DNLI
+$14.9M
4
REPL icon
Replimune Group
REPL
+$14.2M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$13M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$254M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$92.6M
3
TVTX icon
Travere Therapeutics
TVTX
+$44M
4
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$37.6M
5
RLMD icon
Relmada Therapeutics
RLMD
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
2 Miscellaneous 0.16%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
26
Nurix Therapeutics
NRIX
$2.65B
$42.6M 0.26%
3,882,125
– –
KNSA icon
27
Kiniksa Pharmaceuticals
KNSA
$5.98B
$41.9M 0.25%
2,799,577
– –
SWTX
28
DELISTED
SpringWorks Therapeutics
SWTX
$39.8M 0.24%
+1,528,538
New +$37.7M
IDYA icon
29
IDEAYA Biosciences
IDYA
$3.67B
$30.3M 0.18%
1,668,355
– –
DNLI icon
30
Denali Therapeutics
DNLI
$3.39B
$30.3M 0.18%
1,088,738
+500,000
+85% +$14.9M
XENE icon
31
Xenon Pharmaceuticals
XENE
$5.64B
$29.6M 0.18%
751,639
– –
VERV
32
DELISTED
Verve Therapeutics
VERV
$27.4M 0.16%
1,416,530
– –
DICE
33
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$26.9M 0.16%
862,207
+273,972
+47% +$8.93M
TVTX icon
34
Travere Therapeutics
TVTX
$6.2B
$25.8M 0.15%
1,225,255
-2,074,754
-63% -$44M
BCYC
35
Bicycle Therapeutics
BCYC
$272M
$25M 0.15%
843,814
– –
ANAB icon
36
AnaptysBio
ANAB
$1.6B
$24M 0.14%
775,924
+348,745
+82% +$9.85M
KRYS icon
37
Krystal Biotech
KRYS
$10.1B
$24M 0.14%
302,716
-119,469
-28% -$8.87M
DBVT
38
DBV Technologies
DBVT
$776M
$22.4M 0.13%
1,461,426
– –
KYNB
39
Kyntra Bio
KYNB
$32.5M
$22M 0.13%
55,008
+22,379
+69% +$8.57M
RARE icon
40
Ultragenyx Pharmaceutical
RARE
$1.34B
$21.8M 0.13%
470,974
– –
HRTX icon
41
Heron Therapeutics
HRTX
$59.9M
$20.3M 0.12%
8,131,678
– –
TSVT
42
DELISTED
2seventy bio
TSVT
$19.3M 0.12%
2,062,744
– –
PRME icon
43
Prime Medicine
PRME
$577M
$19.1M 0.11%
+1,028,466
New +$18.6M
BMEA icon
44
Biomea Fusion
BMEA
$129M
$17.7M 0.11%
2,104,559
– –
BLUE
45
DELISTED
bluebird bio
BLUE
$17.3M 0.1%
124,986
– –
SPRY icon
46
ARS Pharmaceuticals
SPRY
$448M
$17.1M 0.1%
+2,006,451
New +$13M
NVTA
47
DELISTED
Invitae Corporation
NVTA
$15.6M 0.09%
8,402,035
– –
OPT
48
DELISTED
Opthea Limited American Depositary Shares
OPT
$14.4M 0.09%
2,691,391
– –
ADAP
49
DELISTED
Adaptimmune Therapeutics
ADAP
$14.4M 0.09%
9,830,877
– –
CBAY
50
DELISTED
Cymabay Therapeutics
CBAY
$13.6M 0.08%
2,170,464
– –
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Baker Bros. Advisors held 128 positions worth $16.7B, up 9.1% from $15.3B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors's Q4 2022 filing shows 13 new, 17 increased, 8 reduced and 15 closed positions. Its largest new stake was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M. The largest sale was Global Blood Therapeutics, Inc., an estimated $254M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Financials.

  • Baker Bros. Advisors's largest Q4 2022 buy was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M.
  • Baker Bros. Advisors added most to Denali Therapeutics in Q4 2022, an estimated $14.9M increase.
  • Baker Bros. Advisors's biggest Q4 2022 reduction was Travere Therapeutics, cutting an estimated $44M.
  • Baker Bros. Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $254M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $16.7B portfolio in Q4 2022.
  • Baker Bros. Advisors opened 13 new positions and closed 15 in Q4 2022.
  • Baker Bros. Advisors's portfolio value rose 9.1% quarter-over-quarter to $16.7B.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.